Replies to post #78844 on Cytodyn Inc (CYDY)

[bobshmob]

Other mab's that are being looked at include:

tocilizumab (targets IL-6; showed promise in trials in China and France; big new trials planned in Europe; one is listed in US, but hasn't started recruiting yet)

JS016 (targets the cv-19 spike protein; Eli Lilly is just beginning work on this little guy...anyone remember PRO140? seems so long ago, but it really wasn't. Leronlimab is ahead in development, but Eli Lilly can move things along more quickly than beloved, but tiny, CYDY; different target, different MOA, different goal. Hopefully, both work out well.)

sarilumab (targets IL-6; has not been performing well and probably won't make it)

S309 (targets the spike protein; nice paper in Nature but still in petri dish, not yet in clinical trials)

A bunch of others are described at https://www.antibodysociety.org/covid-19/

Another to keep your eye on is baricitinib, which is not a mab, but Eli Lilly and Gilead appear to be working together to set it up as a combo therapy with remdesivir.

And then there are convalescent plasma studies that take a different approach to monoclonal antibodies. These are on people's radars as well, maybe even more so than the leronlimabs and tocilizumabs of the world.